Bone is a dynamic tissue that constantly remodels by balancing osteoblast-mediated bone formation and osteoclast-mediated bone resorption. The disruption of this tissue homeostasis causes several devastating human diseases including osteoporosis, arthritis and bone metastasis of cancers, leading to severe pain, fractures, life-threatening hypercalcemia, limited mobility and increased mortality. The nuclear receptor PPAR3 (peroxisome proliferator-activated receptor-3) is a critical regulator of energy metabolism and an important therapeutic target for treating the escalating obesity and diabetes epidemic. Emerging evidence suggests that PPAR3 also modulates bone turnover. We discovered that activation of PPAR3 promotes osteoclast differentiation and bone resorption. It has also been shown to suppress osteoblast differentiation and bone formation. Importantly, these findings unravel a central role for PPAR3 in the connection between mineral and energy metabolism, linking skeletal disorders such as osteoporosis with metabolic syndrome hallmarked by obesity, diabetes and atherosclerosis. Synthetic PPAR3 ligands thiazolidinediones (TZDs) are FDA-approved drugs for insulin resistance and type 2 diabetes. Recent clinical trials have reported that long-term use of TZDs increased fracture rates among diabetic patients. Thus, it is of paramount importance to understand how PPAR3 regulates bone metabolism. In this proposal, we hypothesize that 1) PPAR3 exerts a biphasic regulation of osteoclastogenesis, at both the early stage of osteoclast lineage commitment and the late stage of osteoclast differentiation;2) this regulation is influenced by the metabolic context and represents a critical mechanism for TZD-mediated bone loss.
In Aim 1, we will determine the cellular mechanisms for osteoclast development by identifying its hematopoietic origin.
In Aim 2, we will determine the molecular mechanisms for osteoclast lineage commitment and PPAR3 regulation.
In Aim 3, we will determine how TZDs induce bone loss in the context of diabetes. A combination of tools will be employed, including mouse genetic and disease models, molecular and cell biology, biochemistry and small molecules. The proposed investigation will elucidate how PPAR3 regulates mineral metabolism by controlling osteoclast lineage commitment, differentiation and function, as well as how this regulation is influenced by energy metabolism. It will open exciting new paths to the understanding of skeletal physiology and its connection with metabolic diseases. Importantly, the outcome of these studies will provide fundamental insights for the treatment of diabetes, as well as other diseases associated with increased bone resorption such as osteoporosis, arthritis and cancer metastasis. Therefore, this investigation will significantly impact the broader scientific, clinical, and patient community.
Recent clinical trials have reported that long-term use of the diabetic drug Avandia, an activator of the nuclear receptor PPAR3 (peroxisome proliferator-activated receptor-3), increases fracture rates among diabetic patients. This proposal investigates the mechanisms by which PPAR3 and Avandia regulate bone resorption and explores the potential influence of obesity and diabetes on this regulation. Insights from these studies will significantly advance our understanding of both basic bone biology and Avandia-mediated skeletal fragility in diabetic patients.
|Jin, Zixue; Wei, Wei; Yang, Marie et al. (2014) Mitochondrial complex I activity suppresses inflammation and enhances bone resorption by shifting macrophage-osteoclast polarization. Cell Metab 20:483-98|
|Wei, Wei; Motoike, Toshiyuki; Krzeszinski, Jing Y et al. (2014) Orexin regulates bone remodeling via a dominant positive central action and a subordinate negative peripheral action. Cell Metab 19:927-40|
|Bornstein, Sheila; Brown, Sue A; Le, Phuong T et al. (2014) FGF-21 and skeletal remodeling during and after lactation in C57BL/6J mice. Endocrinology 155:3516-26|
|Krzeszinski, Jing Y; Wei, Wei; Huynh, HoangDinh et al. (2014) miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature 512:431-5|
|Wan, Yihong (2013) iBAT on bone. Endocrinology 154:2579-80|
|Wan, Yihong (2013) Bone marrow mesenchymal stem cells: fat on and blast off by FGF21. Int J Biochem Cell Biol 45:546-9|
|Jin, Zixue; Wei, Wei; Dechow, Paul C et al. (2013) HDAC7 inhibits osteoclastogenesis by reversing RANKL-triggered ýý-catenin switch. Mol Endocrinol 27:325-35|
|Wei, Wei; Dutchak, Paul A; Wang, Xunde et al. (2012) Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor ýý. Proc Natl Acad Sci U S A 109:3143-8|
|Wei, Wei; Zeve, Daniel; Suh, Jae Myoung et al. (2011) Biphasic and dosage-dependent regulation of osteoclastogenesis by ýý-catenin. Mol Cell Biol 31:4706-19|
|Wei, Wei; Zeve, Daniel; Wang, Xueqian et al. (2011) Osteoclast progenitors reside in the peroxisome proliferator-activated receptor ?-expressing bone marrow cell population. Mol Cell Biol 31:4692-705|